Format

Send to

Choose Destination
Mol Genet Metab. 2014 Mar;111(3):374-381. doi: 10.1016/j.ymgme.2013.12.007. Epub 2013 Dec 17.

Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Author information

1
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gwengunn@uab.edu.
2
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: dyy@uab.edu.
3
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: dalian@uab.edu.
4
The Edith and Joseph Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: chvalery@tx.technion.ac.il.
5
The Edith and Joseph Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: jkumar@tx.technion.ac.il.
6
Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: trs@uab.edu.
7
The Edith and Joseph Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: chtimor@techunix.technion.ac.il.
8
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: dbedwell@uab.edu.
9
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: kkeeling@uab.edu.

Abstract

Nonsense suppression therapy is a therapeutic approach aimed at treating genetic diseases caused by in-frame premature termination codons (PTCs; also commonly known as nonsense mutations). This approach utilizes compounds that suppress translation termination at PTCs, which allows translation to continue and partial levels of deficient protein function to be restored. We hypothesize that suppression therapy can attenuate the lysosomal storage disease mucopolysaccharidosis type I-Hurler (MPS I-H), the severe form of α-L-iduronidase deficiency. α-L-iduronidase participates in glycosaminoglycan (GAG) catabolism and its insufficiency causes progressive GAG accumulation and onset of the MPS I-H phenotype, which consists of multiple somatic and neurological defects. 60-80% of MPS I-H patients carry a nonsense mutation in the IDUA gene. We previously showed that 2-week treatment with the designer aminoglycoside NB84 restored enough α-L-iduronidase function via PTC suppression to reduce tissue GAG accumulation in the Idua(tm1Kmke) MPS I-H mouse model, which carries a PTC homologous to the human IDUA-W402X nonsense mutation. Here we report that long-term NB84 administration maintains α-L-iduronidase activity and GAG reduction in Idua(tm1Kmke) mice throughout a 28-week treatment period. An examination of more complex MPS I-H phenotypes in Idua(tm1Kmke) mice following 28-week NB84 treatment revealed significant moderation of the disease in multiple tissues, including the brain, heart and bone, that are resistant to current MPS I-H therapies. This study represents the first demonstration that long-term nonsense suppression therapy can moderate progression of a genetic disease.

KEYWORDS:

Lysosomal storage disease; Mucopolysaccharidosis I-Hurler; Nonsense mutations; Nonsense suppression; Premature termination codons; Readthrough

PMID:
24411223
PMCID:
PMC3943726
DOI:
10.1016/j.ymgme.2013.12.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center